Phase 1/2 Trials Begin for PSMA-R2 Compounds Being Tested for Prostate Cancer Treatment, Diagnostics

Phase 1/2 Trials Begin for PSMA-R2 Compounds Being Tested for Prostate Cancer Treatment, Diagnostics
Two Phase 1/2 clinical trials testing PSMA-R2-based treatment and diagnostic candidates for prostate cancer have begun dosing their first patients, Advanced Accelerator Applications (AAA) announced in a press release. PSMA-R2 is a urea-based radioligand — a radioactive-labeled biochemical compound — of the protein prostate-specific membrane antigen (PSMA), which is frequently overproduced in prostate cancer cells. It is part of AAA’s
Subscribe or to access all post and page content.